2004
DOI: 10.1200/jco.2004.22.90140.582
|View full text |Cite
|
Sign up to set email alerts
|

Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0

Year Published

2006
2006
2016
2016

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(9 citation statements)
references
References 0 publications
0
9
0
Order By: Relevance
“…DCE‐MRI is able to demonstrate intrinsic differences in the behavior of the distribution of contrast medium that exist between different tissue types, and thus has potential to play multiple roles in cancer management (1–3). A number of studies in various tumor sites (including the breast, rectum, and brain) have shown that changes in tumor microvasculature as demonstrated by DCE‐MRI are useful for predicting and assessing the extent of response to a variety of treatments (4–10). The advantage of DCE‐MRI in predicting response to therapy is that it can quantitatively assess vascular function and does not rely on changes in tumor size to assess the efficacy of treatment.…”
mentioning
confidence: 99%
“…DCE‐MRI is able to demonstrate intrinsic differences in the behavior of the distribution of contrast medium that exist between different tissue types, and thus has potential to play multiple roles in cancer management (1–3). A number of studies in various tumor sites (including the breast, rectum, and brain) have shown that changes in tumor microvasculature as demonstrated by DCE‐MRI are useful for predicting and assessing the extent of response to a variety of treatments (4–10). The advantage of DCE‐MRI in predicting response to therapy is that it can quantitatively assess vascular function and does not rely on changes in tumor size to assess the efficacy of treatment.…”
mentioning
confidence: 99%
“…One slice from the pre-treatment scan of each patient was used for analysis. Data from this study have been previously reported [13,3].…”
Section: In Vivo Validationmentioning
confidence: 94%
“…For the clinical evaluation of our approach we used data of six breast cancer patients who have participated in a breast cancer study which has previously been reported on and which has already been analyzed [44,45,26,10]. Per breast cancer patient, we used two scans recorded by a 1.5 T Siemens MAGNETOM Symphony scanner (Repetition time (TR) = 11 ms, Echo Time (TE) = 4.7 ms).…”
Section: Application To Dce-mri Data 41 Description Of the Datamentioning
confidence: 99%